Adionuclide therapy for metastatic castration-resistant prostate cancer:New advances
WANG Shi-hao
GU Yu-feng
XU Song
Abstract：Prostate cancer(PCa)is one of the most common tumors of the male urogenital system,ranking the second among male malignancies worldwide.Age is a major risk factor for PCa,and population aging leads to an increasing incidence of the malignan-cy.Androgen-deprivation therapy(ADT)is currently the first-line treatment of PCa,but with the advance of the tumor,many of the patients become resistant to ADT and develop castration-resistant prostate cancer(CRPC),which marks a transition of PCa to a hor-mone-refractory state associated with a poor prognosis.Metastatic CRPC(mCRPC)is the terminal stage of the disease and a leading cause of death.Despite many new advances in the treatment of mCRPC,its prognosis remains poor.For patients with mCRPC,classi-cal treatment options with chemotherapy and androgen-blocking agents have limited survival benefit,and radionuclide therapy has be-come a novel therapeutic option for mCRPC.This paper focuses on the development of the radionuclide therapy for mCRPC in recent years.
Keywords：radionuclidescastration-resistanceprostate cancer
Publication Date：2023-03-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 275-281 )